Table 1. Selected genes that carried signatures of accelerated evolution in the promoters.
| Genes | Position | Cancer type | Cohort (total samples) | # samples with significant SASE | FDR adjusted P-value |
|---|---|---|---|---|---|
| BTG2 | chr1:203274619:203278730:+1 | Malignant Lymphoma | MALY-DE (44) | 4 | 9.29E-10 |
| TCL1A | chr14:96176304:96180533:-1 | Malignant Lymphoma | MALY-DE (44) | 4 | 7.88E-05 |
| MYC | chr8:128747680:128753674:+1 | Malignant Lymphoma | MALY-DE (44) | 3 | 1.35E-04 |
| BCL2 | chr18:60790579:60987361:-1 | Malignant Lymphoma | MALY-DE (44) | 5 | 2.60E-04 |
| CD83 | chr6:14117872:14137149:+1 | Malignant Lymphoma | MALY-DE (44) | 3 | 1.07E-03 |
| RBM5 | chr3:50126341:50156454:+1 | Melanoma | Melanoma (25) | 7 | 3.07E-07 |
| WWOX | chr16:78133310–79246564:1 | Lung Adenocarenoma | LUAD (32) | 4 | 7.30E-04 |
| CCDC168 | chr13:103381801:103389159:-1 | Colon cancer | COAD-US (19) | 4 | 1.04E-04 |
| CCDC168 | chr13:103381801:103389159:-1 | Endometrial cancer | UCEC-US (131) | 4 | 1.64E-08 |
Only those cases that are found in multiple cancer types, show associated gene expression changes, or clinical attributes are listed. The complete catalog of genes carrying signatures of accelerated evolution in the promoter are shown in Supplementary Table S1.